DWTX · Insider Trading
Dogwood Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by DWTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Rosa Abel De La | Director | A | +16,800 deriv. | — |
| 2026-06-17 | John C Thomas | Director | A | +16,800 deriv. | — |
| 2026-06-17 | David R Keefer | Director | A | +16,800 deriv. | — |
| 2026-06-17 | Richard James Whitley | Director | A | +16,800 deriv. | — |
| 2026-03-06 | Roger Michael Gendreau | CHIEF MEDICAL OFFICER | A | +82,500 deriv. | — |
| 2026-03-06 | Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER | A | +330,000 deriv. | — |
| 2026-03-06 | Angela Walsh | Chief Financial Officer | A | +82,500 deriv. | — |
| 2026-03-06 | Ralph Grosswald | SVP OF OPERATIONS | A | +82,500 deriv. | — |
| 2025-12-05 | Angela Walsh | Chief Financial Officer | A | +150,000 deriv. | — |
| 2025-12-05 | Roger Michael Gendreau | CHIEF MEDICAL OFFICER | A | +150,000 deriv. | — |
| 2025-12-05 | Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER | A | +460,000 deriv. | — |
| 2025-12-05 | Ralph Grosswald | SVP OF OPERATIONS | A | +150,000 deriv. | — |
| 2025-11-25 | Sealbond Ltd | Director | C | +73,360,764 | — |
| 2025-07-01 | Richard James Whitley | Director | A | +2,362 deriv. | — |
| 2025-07-01 | Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER | A | +40,000 deriv. | — |
| 2025-07-01 | Roger Michael Gendreau | CHIEF MEDICAL OFFICER | A | +12,075 deriv. | — |
| 2025-07-01 | Angela Walsh | Chief Financial Officer | A | +12,075 deriv. | — |
| 2025-07-01 | John C Thomas | Director | A | +2,362 deriv. | — |
| 2025-07-01 | Rosa Abel De La | Director | A | +2,362 deriv. | — |
| 2025-07-01 | Ralph Grosswald | SVP OF OPERATIONS | A | +12,075 deriv. | — |
| 2025-07-01 | David R Keefer | Director | A | +2,362 deriv. | — |
| 2025-06-23 | David R Keefer | Director | A | +420 deriv. | — |
| 2025-06-23 | John C Thomas | Director | A | +420 deriv. | — |
| 2025-06-23 | Richard James Whitley | Director | A | +420 deriv. | — |
| 2025-06-23 | Rosa Abel De La | Director | A | +420 deriv. | — |
| 2025-03-17 | CK Life Sciences Intl (Holdings) Inc | Director | A | +284 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sealbond Ltd | Director | 24,664,971 | $27.38M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DWTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.